Molecular biology of prostatic intraepithelial neoplasia

Prostate

Volumn 29, Issue 2, 1996, Pages 117-134

  Bostwick, David G ^a,c   Pacelli, Anna ^a   Lopez Beltran, Antonio ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c MAYO CLINIC   (United States)

Author keywords

carcinoma; genetic analysis; growth factor; molecular biology; oncogenes; prostate; prostatic intraepithelial neoplasia; tumor suppressor

Indexed keywords

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CARCINOMA IN SITU; CELL DIFFERENTIATION; GENETIC ANALYSIS; GROWTH REGULATION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; ONCOGENE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; DNA, NEOPLASM; GENOTYPE; HUMANS; MALE; PHENOTYPE; PLOIDIES; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0029848515     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199608)29:2<117::AID-PROS7>3.0.CO;2-C     Document Type: Article

References (157)

1. Bostwick DG: High grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Cancer 75:1823-1836, 1995.
2. Graham SD Jr, Bostwick DG, Hoisaeter A, et al: Report of the committee on staging and pathology. Cancer 70(suppl):359-361, 1992.
3. McNeal JE, Bostwick DG: Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 17:64-71, 1986.
4. Bostwick DG, Brawer MK: Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59:788-794, 1987.
5. Qian J, Wollan P, Bostwick DG: The extent and multicentricity of high grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1996 (in press).
6. Drago JR, Mostofi FK, Lee F: Introductory remarks and workshop summary. Urology 34(suppl):2-3, 1989.
7. Davidson D, Bostwick DG, Qian J, Wollan PC, Oesterling JE, Rudders RA, Siroky M, Stilmant M: Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: Predictive accuracy in needle biopsies. J Urol 154:1295-1299, 1995.
8. Keetch DW, Humphrey P, Stahl D, Smith DS, Catalona WJ: Morphometric analysis and clinical follow-up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 154:347-351, 1995.
9. Montironi R, Bostwick DG, Bonkhoff H, Cockett A, Helpap B, Troncoso P, Waters D: Workshop #1: Origins of Prostate Cancer. Cancer 1996 (in press).
10. Petein M, Michel P, Van Velthoven R, et al: Morphonuclear relationship between prostatic intraepithelial neoplasia and cancers as assessed by digital cell image analysis. Am J Clin Pathol 96:628-634, 1991.
11. Montironi R, Scarpelli M, Sisti S, et al: Quantitative analysis of prostatic intra-epithelial neoplasia on tissue sections. Anal Quant Cytol Histol 12:366-372, 1990.
12. Sesterhenn IA, Becker RL, Avallone FA, Mostofi FK, Lin TE, Davis CJ: Image analysis of nucleoli and nucleolar organizer regions in prostatic hyperplasia, intraepithelial neoplasia, and prostatic carcinoma. J Urogen Pathol 1:61-74, 1991.
13. Helpap B: Observations on the number, size and location of nucleoli in hyperplastic and neoplastic prostatic disease. Histopathology 13:203-211, 1988.
14. Layfield LJ, Goldstein NS: Morphometric analysis of borderline atypia in prostatic aspiration biopsy specimen. Anal Quant Cytol Histol 13:288-292, 1991.
15. Berner A, Danielsen HE, Pettersen EO, Fossa SD, Reith A, Nesland JM: DNA distribution in the prostate. Normal gland, benign and premalignant lesions, and subsequent adenocarcinomas. Anal Quant Cytol Histol 15: 247-252, 1993.
16. De La Torre, Haggman M, Brandstedt S, et al: Prostatic intraepithelial neoplasia and invasive carcinoma in total prostatectomy specimens: Distribution, volume and DNA ploidy. Br J Urol 72:207-213, 1993.
17. Baretton GB, Vogt T, Blasenbreu S, et al: Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: An image cytometric study. Hum Pathol 25:506-513, 1994.
18. Sakr WA, Haas GP, Drozdowicz SM, et al: Nuclear DNA content of prostatic carcinoma and intraepithelial neoplasia (PIN) in young males. An image analysis study. Mod Pathol 5:58A, 1992.
19. Amin MB, Schultz DS, Zarbo RJ, et al: Computerized static DNA ploidy analysis of prostatic intraepithelial neoplasia. Arch Pathol Lab Med 117:794-798, 1993.
20. Weinberg DS, Weidner N: Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma. Arch Pathol Lab Med 117:1132-1137, 1993.
21. Crissman JD, Sakr WA, Hussein ME, et al: DNA Quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate. Prostate 22:155-162, 1993.
22. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55:5408-5414, 1995.
23. Myers RB, Srivastava S, Oelschlager DK, et al: Expression of p160erbB-3 and 185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86:1140-1145, 1994.
24. Colombel M, Symmans F, Gil S, et al: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400, 1993.
25. Montironi R, Magi Galluzzi C, Diamanti L, et al: Prostatic intraepithelial neoplasia. Expression and location of proliferating cell nuclear antigen (PCNA) in epithelial, endothelial and stromal nuclei. Virchows Arch [A] Pathol Anat 422:185-192, 1993.
26. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994.
27. Boag AH, Young ID: Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 144:585-591, 1994.
28. Boag AH, Young ID: Immunohistochemical analysis of type IV collagenase expression in prostatic hyperplasia and adenocarcinoma. Mod Pathol 6:65-68, 1993.
29. Montironi R, Magi Galluzzi C, Diamanti L, et al: Prostatic intraepithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract 189:542-548, 1993.
30. McNeal JE, Alroy J, Leav I, et al: Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am J Clin Pathol 90:23-32, 1988.
31. Humphrey PA: Mucin in severe dysplasia in the prostate. Surg Pathol 4:137-143, 1991.
32. Nagle RB, Brawer MK, Kittelson J, et al: Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol 138:119-128, 1991.
33. Perlman EJ, Epstein JI: Blood group antigen expression in dysplasia and adenocarcinoma of the prostate. Am J Surg Pathol 14:810-818, 1990.
34. Bostwick DG, Dousa MK, Crawford BG, Wollan PC: Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 18:1240-1246, 1994.
35. Deschenes J, Weidner N: Nucleolar organizer regions (NOR) in hyperplastic and neoplastic prostate disease. Am J Surg Pathol 14:1148-1155, 1990.
36. Min KW, Jin J-K, Blank J, Hemstreet G: AgNOR in the human prostatic gland. Am J Clin Pathol 95:508-512, 1990.
37. Sentinelli S: Mucins in prostatic intra-epithelial neoplasia and prostatic carcinoma. Histopathology 22:271-274, 1993.
38. McNeal JE, Leav I, Alroy J, Skutelsky E: Differential lectin staining of central and peripheral zones of the prostate and alterations in dysplasia. Am J Clin Pathol 89:41-48, 1988.
39. McNeal JE, Villers A, Redwine EA, Freiha FS, Stamey TA: Microcarcinoma in the prostate: Its association with duct-acinar dysplasia. Hum Pathol 22:644-652, 1991.
40. Algaba F, Trias I, Lopez L, Rodriguez-Vallejo JM, Gonzalez-Esteban J: Neuroendocrine cells in peripheral prostatic zone: Age, prostatic intraepithelial neoplasia and latent cancer-related changes. Eur Urol 27:329-333, 1995.
41. Nakopoulou L, Stefanaki K, Deliveliotis C, Lazaris AC, Kondothanasis D, Dimopoulos KA: Neuroendocrine differentiation and proliferation state estimation in hyperplastic and neoplastic human prostate. J Urol Pathol 1996 (in press).
42. De la Torre M, Eklov S, Haggman M, Bjork P, Busch C, Nilsson S: Elevated expression of estramustine binding protein (EMBP) in prostatic intraepithelial neoplasia (PIN) compared with malignant and benign prostatic epithelia. Prostate 25:125-131, 1994.
43. Bonkhoff H, Stein U, Welter C, Remberger K: Differential expression of the pS2 protein in the human prostate and prostate cancer: Association with premalignant changes and neuroendocrine differentiation. Hum Pathol 26:824-828, 1995.
44. Epstein JI, Carmichael M, Partin AW: OA-518 (Fatty Acid Synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. Urology 45:81-86, 1995.
45. Gould VE, Doljanskaia V, Gooch G, Bostwick DG: Immunolocalization of glycoprotein A-80 in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum Pathol (in press).
46. Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P: TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. J Urol 153:1575-1579, 1995.
47. x and related carbohydrate antigens in the prostate. Hum Pathol 26:735-739, 1995.
48. Myers RB, Srivastava S, Grizzle WE: Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J Urol 153:1572-1574, 1995.
49. Gao X, Grignon DJ, Chbihi T, Zacharek A, Chen YQ, Sakr W, Porter AT, Crissman JD, Pontes JE, Powell IJ, Honn KV: Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46:227-237, 1995.
50. Iwamura M, Gershagen S, Lapets O, Myones R, Abrahamsson P, Cockett ATK, Deftos LJ, di Santi'Agnese PA: Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia. Hum Pathol 26:797-801, 1995.
51. x: A new prognostic parameter in metastatic prostate cancer. Cancer Res 55:1817-1819, 1995.
52. Kleinerman DI, Troncoso P, Lin S, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh J: Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: Implication as a tumor suppressor. Cancer Res 55:1215-1220, 1995.
53. Umbas R, Isaacs WB, Bringuier PP, Schaafsma E, Karthaus HFM, Oosterhof GON, Debryne FMJ, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54:3929-3933, 1994.
54. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB: Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res 53:3585-3590, 1993.
55. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG: The expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996 (in press).
56. Rembrink K, Otto T, Goespel M, Enzawi SM, Rubben H: E-cadherin expression of the epithelial cell-cell-adhesion molecule in prostatic carcinoma and normal prostate. Invest Urol 5:24-27, 1994.
57. Nagle RB, Hao J, Know JD, Dalkin BL, Clark V, Cress AE: Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 146:1498-1507, 1995.
58. Knox JD, Cress AE, Clark V, Manriquez L, Affinito K, Dalkin BL, Nagle RB: Differential expression of extracellular matrix molecules and the alpha6-integrins in the normal and neoplastic prostate. Am J Pathol 145: 167-174, 1994.
59. Bonkhoff H, Stein U, Remberger K: Differential expression of alpha6 and alpha2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: Simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol 24:243-248, 1993.
60. Stearns ME, Stearns M: Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion. Cancer Metast Rev 12:39-52, 1993.
61. Powell WC, Know JD, Navre M, Grogan TM, Kittelson J, Nagle RB, Bowden GT: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53:417-422, 1993.
62. Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J: Serums metalloproteinases and their inhibitors: Markers for malignant potential. Brit J Cancer 70: 506-512, 1994.
63. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z: Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in expiant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53:4493-4498, 1993.
64. Hamdy FC, Fadlon EJ, Cottam D, Lawry J, Thurrell W, Silcocks PB, Anderson JB, Williams JL, Rees RC: Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69:177-182, 1994.
65. Sinha AA, Gleason DF, Staley NA, Wilson JM, Sameni M, Sloane BF: Cathepsin B in angiogenesis of human prostate: An immunohistochemical and immunoelectron microsopic analysis. Anat Rec 241:353-362, 1995.
66. Bigler SA, Deering RE, Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24:220-226, 1993.
67. Hanks GE, D'Amico A, Epstein BE, Schultheiss TE: Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 27: 125-127, 1993.
68. Schmid HP, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71:2031-2040, 1993.
69. Gainnulis I, Montironi R, Galluzzi CM, et al: Frequency and location of mitoses in prostatic intraepithelial neoplasia (PIN). Anticancer Res 13:2447-2452, 1993.
70. Montironi R, Magi Galluzzi C, Scarpelli M, Giannulis I, Diamanti L: Occurrence of cell death (apoptosis) in prostatic intra-epithelial neoplasia. Virchows Arch [A] Pathol Anat 423:351-357, 1993.
71. Montironi R, Magi-Galluzzi C, Fabris G: Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract 191:873-880, 1995.
72. Steiner MS: Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol 153:1085-1096, 1995.
73. Ware JL: Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. Cancer Metast Rev 12:287-301, 1993.
74. Myers RB, Kudlow JE, Grizzle WE: Expression of transforming growth factor-alpha, epidermal growth factor and the epidermal growth factor receptor in adenocarcinoma of the prostate and benign prostatic hyperplasia. Mod Pathol 6:733-737, 1993.
75. Turkeri LN, Sakr WA, Wykes SM, Grignon DJ, Pontes JE, Macoska JA: Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. Prostate 25:199-205, 1994.
76. Davies P, Eaton CL: Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate. Prostate 14:123-132, 1989.
77. Shaikh N, Lai L, McLoughlin J, Clark D, Williams G: Quantitative analysis of epidermal growth factor in human benign prostatic hyperplasia and prostatic adenocarcinoma and its prognostic significance. Anticancer Res 10:873-877, 1990.
78. Robertson CN, Roberson KM, Herzberg AJ, Kerns BJM, Dodges RK, Paulson DF: Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues. Surg Oncol 3:237-242, 1994.
79. Maddy SQ, Chisholm GD, Busuttil A, Habib FK: Epidermal growth factor receptors in human prostate cancer: Correlation with histological differentiation of the tumor. Br J Cancer 60:41-44, 1989.
80. Ibrahim GK, Kerns BM, MacDonald JA, Ibrahim SN, Kinney RB, Humphrey PA, Robertson CN: Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 149:170-173, 1993.
81. Montone KT, Tomaszewski JE: In situ hybridization for epidermal growth factor receptor (EGFR) external domain transcripts in prostatic adenocarcinoma. J Clin Lab Anal 7:188-195, 1993.
82. Maygarden SJ, Strom S, Ware JL: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia. Arch Pathol Lab Med 116:269-273, 1992.
83. Myers RB, Lampejo O, Herrera GA, Srivastava S, Oelschlager D, Brown DA, Waterbor JW, Grizzle WE: TGF-alpha expression is a relatively late event in the progression of prostatic adenocarcinoma. J Urol Pathol 3:195-104, 1995.
84. Harper ME, Goddard L, Glynne-Jones E, Wilson DW, Price-Thomas M, Peeling WB, Griffiths K: An immunocytochemical analysis of TGF-alpha expression in benign and malignant prostatic tumors. Prostate 23:9-23, 1993.
85. Cohen DW, Simak R, Rair WR, Melamed J, Scher HI, Cordon-Cardo C: Expression of transforming growth factor-μ, and the epidermal growth factor receptor in human prostate tissues. J Urol 152:2120-2124, 1994.
86. Ibrahim GK, MacDonald JA, Kerns BJM, et al: Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues. Surg Oncol 1:151-155, 1992.
87. neu) in prostate tumors: An immunohistochemical study. Prostate 23:329-336, 1993.
88. Visakorpi T, Kallioniemi O-P, Koivula T, et al: Expression of epidermal growth factor receptor and ERBB2 (Her-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 5:643-648, 1992.
89. McCann A, Dervan PA, Johnston PA, et al: c-erbB-2 oncoprotein expression in primary human rumors. Cancer 65:88-94, 1990.
90. Ware JL, Maygarden SJ, Koontz WW Jr, et al: Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 22:254-259, 1991.
91. Kuhn EJ, Kurnot RA, Sesterhenn IA, et al: Expression of the c-erbB-2 (HER2/neu) oncoprotein in human prostatic carcinoma. J Urol 150:1427-1433, 1993.
92. Grizzle WE, Myers RB, Arnold MM, Srivastava S: Evaluation of biomarkers in breast and prostate cancer. J Cell Biochem 19(suppl):259-266, 1994.
93. Zhau HE, Wan DS, Zhou J, et al: Expression of c-erbB-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5:320-327, 1992.
94. Sikes RA, Chung LWK: Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 52:3174-3178, 1992.
95. Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG: Decrease of prostatic intraepithelial neoplasia (PIN) following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 44:91-95, 1994.
96. Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G: Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol 47:906-913, 1994.
97. Bostwick DG, Burke HB, Wheeler TM, Chung LWK, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, Grizzle WE, Grignon DJ: The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J CeU Biochem 19(suppl):283-289, 1994.
98. Sadasivan R, Morgan R, Jennings S, et al: Overexpression of HER2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 150:126-131, 1993.
99. Veltri RW, Partin AW, Epstein JI, Marley GM, Miller CM, Singer DS, Patton KP, Criley SR, Coffey DS: Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem 19(suppl): 249-258, 1994.
100. Mellon K, Thompson S, Charlton RG, et al: p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147:496-499, 1992.
101. Ross JS, Nazeer T, Church K, et al: Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 72:3020-3028, 1993.
102. Thompson DM, Gill GN: The EGF receptor, structure, regulation, and potential role in malignancy. Cancer Surv 4:767-788, 1985.
103. Eklov S, Funa K, Nordgren H, Olofsson A, Kanzaki T, Miyazono K, Nilsson S: Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue. Cancer Res 53:3193-3197, 1993.
104. Fudge K, Wang CY, Stearns ME: Immunohistochemistry analysis of platelet-deprive growth factor A and B chains and platelet-derived growth factor alpha and Beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostatic adenocarcinomas. Mod Pathol 7:549-554, 1994.
105. Fudge K, Bostwick DG, Stearns ME: Platelet-derived growth factor A and B chains and the alpha and Beta receptors in prostatic intraepithelial neoplasia. Prostate 27:1-5, 1996.
106. Ross JS, Nazeer T, Figge HL, Fisher HAG, Rifkin MD: Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status. Am J Clin Pathol 104:36-41, 1995.
107. Maygarden SJ, Novotny DB, Moul JW, Bae VL, Ware JL: Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Mod Pathol 7:930-936, 1994.
108. Makar R, Mason A, Kittelson JM, Bowden GT, Cress AE, Nagle RB: Immunohistochemical analysis of cathepsin D in prostate carcinoma. Mod Pathol 7:747-751, 1994.
109. Sinha AA, Wilson MJ, Gleason DF, Reddy PK, Sameni M, Sloane BF: Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate 26: 171-178, 1995.
110. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LWK: C-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154:293-298, 1995.
111. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147:386-396, 1995.
112. Latil A, Baron J-C, Cussenot O, Fournier G, Soussi T, Boccod-Gibod L, Le Duc A, Rouesse J, Lidereau R: Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q. Genes Chromosom Cancer 11:119-125, 1994.
113. Zitzelsberger H, Szves S, Weier HU, et al: Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridization (FISH) on paraffin embedded tissue sections with centromere-specific DNA probes. J Pathol 172:325-335, 1994.
114. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WL: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia (PIN). Cancer Res 55:2959-2962, 1995.
115. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 153:249-254, 1995.
116. Zenklusen JC, Thompson JC, Troncoso P, Kagan J, Cont CJ: Loss of heterozygosity in human primary prostatic carcinomas: A possible tumor suppressor gene at 7q31.1. Cancer Res 54:6870-6873, 1994.
117. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR: Allelic loss in locally metastatic multisampled prostate cancer. Cancer Res 54:3273-3277, 1994.
118. Bergerheim US, Kunimi K, Collins VP, Ekman P: Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosom Cancer 3:215-220, 1991.
119. Bostwick DG, Qian J: Atypical adenomatous hyperplasia of the prostate: Relationship with carcinoma in 217 whole mount radical prostatectomies. Am J Surg Pathol 19:506-518, 1995.
120. Quinn BD, Cho KR, Epstein JI: Relationship of severe dysplasia to stage B adenocarcinoma of prostate. Cancer 65:2328-2337, 1990.
121. Alers CA, Krijtenburg PJ, Vissers KJ, Bosman FT, van der Kwast TH, Dekken H: Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: Analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosom Cancer 12:241-250, 1995.
122. Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, Thompson TC, Scardino PT: Some small prostate cancers are nondiploid by nuclear image analysis: Correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 151: 1301-1307, 1994.
123. Macoska JA, Micale MA, Sakr WA, Benson PD, Wolman SR: Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis. Genes Chromosom Cancer 8:88-97, 1993.
124. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB: Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization. Cancer Res 54:3574-3579, 1994.
125. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh E, Larson-Keller J, Lieber MM, Jenkins RB: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54:3998-4002, 1994.
126. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LWK, Liang JC: Trisomy 7: A potential cytogenetic markers of human prostate cancer progression. Genes Chromosom Cancer 9:19-27, 1994.
127. Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB: Chromosomal aneusomies detected by fluorescence in situ hybridization analysis in clinically localized prostate carcinoma. J Urol 152:1157-1162, 1994.
128. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG: Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostaric carcinogenesis. Proc Natl Acad Sci USA 91:11733-11737, 1994.
129. Van der Kwast TH, Ruizeveld de Winter JA, Trapman J: Androgen receptor expression in human prostate cancer. J Urol Pathol 3:200-222, 1995.
130. Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398, 1995.
131. Ruizeveld de Winter JA, Janssen PJA, Sleddens HMAB, et al: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735-746, 1994.
132. Batsakis JG, El-Naggar AK: p53: Fifteen years after discovery. Adv Anat Pathol 2:71-88, 1995.
133. Bookstein R, MacGrogan D, Hilsenbeck SG, et al: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-3373, 1993.
134. Effert PJ, McCoy RH, Walther PJ, et al: p53 gene alterations in human prostate carcinoma. J Urol 150:257-261, 1993.
135. Sandberg AA: Chromosomal abnormalities and related events in prostate cancer. Hum Pathol 23:368-380, 1992.
136. Kubota Y, Shuin T, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, Danenberg PV: Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27:18-24, 1995.
137. Fan K, Dao DD, Schutz M, Fink LM: Loss of heterozygosity and overexpression of p53 gene in human primary prostatic adenocarcinoma. Diagn Mol Pathol 3:265-270, 1994.
138. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LWK: Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45:470-475, 1995.
139. Myers RB, Oelschlager D, Srivastava S, Grizzle WE: Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinoma. Prostate 25:243-248, 1994.
140. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 47:92-101, 1995.
141. Sarkar FH, Sakr W, Li YW, et al: Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 21:145-152, 1992.
142. Bookstein R, Rio P, Madreperla SA, et al: Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87:7762-7766, 1990.
143. Brooks JD, Bova GS, Isaacs WB: Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinoma. Prostate 26:35-39, 1995.
144. Phillips SMA, Morton DG, Lee SJ, Wallace DMA, Neoptelemos JP: Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci in chromosomes 10p, 10q, and 16q in human prostate cancer. Br J Urol 73:390-395, 1994.
145. Igawa M, Rukstalis DB, Tanabe T, Chodak GW: High levels of nm23 expression are related to cell proliferation in human prostate cancer. Cancer Res 54:1313-1318, 1994.
146. Konishi N, Nakaoka S, Tsuzuki T, Matsumoto K, Kitahori Y, Hiasa Y, Urano T, Shiku H: Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma. Jpn J Cancer Res 84:1050-1054, 1993.
147. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886, 1995.
148. Shen Rm Su ZZ, Olsson CA, Fisher PB: Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. Proc Natl Acad Sci USA 92:6778-6782, 1995.
149. Brawer MK, Bigler SA, Sohlberg OE, Nagle RB, Lange PH: Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology 38:103-107, 1991.
150. Weinstein MH, Epstein JI: Significance of high grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 24:624-629, 1993.
151. Park C, Galang C, Johennig P, et al: Follow-up aspiration biopsies for dysplasia of the prostate. Lab Invest 60:70A, 1989.
152. Markham CW: Prostatic intraepithelial neoplasia: Detection and correlation with invasive cancer in fine-needle biopsy. Urology 24(suppl):57-61, 1989.
153. Lee F, Torp-Pedersen ST, Carroll JT, Siders DB, Christensen-Day C, Mitchell AE: Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia. Urology 24(suppl): 4-8, 1989.
154. Shinohara K, Scardino PT, Carter SSC, Wheeler TM: Pathologic basis of the sonographic appearance of the normal and malignant prostate. Urol Clin North Am 16:675-691, 1989.
155. Brawer MK, Lange PH: Prostate-specific antigen and premalignant change: Implications for early detection. CA-A Cancer J 39:361-375, 1989.
156. Ronnett BM, Carmichael MJ, Carter HB, et al: Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol 150:386-389, 1993.
157. Alexander EE, Qian J, Wollan PC, Myers RP, Bostwick DG: Prostatic intraepithelial neoplasia does not raise serum prostate specific antigen. Urology (in press).